|
|
|
|
|
|
Reference
Scientific Studies
Submitted by admin on Sun, 11/20/2011 - 03:04
FOR IMMEDIATE RELEASE
Orthomolecular Medicine News Service, October 12, 2011
What Kind of Medical Study Would Have Grandma Believe that Her Daily Multivitamin is Dangerous?by Robert G. Smith, PhD(OMNS, Oct 12, 2011)
A newly released study suggests that multivitamin and nutrient
supplements can increase the mortality rate in older women [1]. However,
there are several concerns about the study's methods and significance.
- The study was observational, in
which participants filled out
a survey about their eating habits and their use of supplements. It
reports only a small increase in overall mortality (1%) from those
taking multivitamins. This is a small effect, not much larger than would
be expected by chance. Generalizing from such a small effect is not
scientific.
- The study
actually reported that taking supplements of B-complex, vitamins C, D,
E, and calcium and magnesium were associated with a lower risk of mortality.
But this was not emphasized in the abstract, leading the non-specialist
to think that all supplements were associated with mortality. The
report did not determine the amounts of vitamin and nutrient supplements
taken, nor whether they were artificial or natural. Further, most of
the association with mortality came from the use of iron and copper
supplements, which are
known to be potentially inflammatory and toxic when taken by older
people, because they tend to accumulate in the
body [2,3,4]. The risk from taking iron supplements should not be
generalized to imply that all vitamin and nutrient supplements are
harmful.
Submitted by admin on Sat, 08/13/2011 - 08:49
SourceCenter for Engineering in Medicine, Shriners Burns Hospital, Boston, MA, USA; Harvard-MIT Division of Health Science and Technology, Cambridge, MA, USA; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Abstract
BACKGROUND & AIMS:Hepatitis C virus (HCV) infection affects 3% of the world population and is the leading cause of chronic liver disease worldwide. Current standard of care is effective in only 50% of the patients, poorly tolerated, and associated with significant side effects and viral resistance. Recently, our group and others demonstrated that the HCV lifecycle is critically
dependent on host lipid metabolism and that its production is metabolically modulated. METHODS: The JFH1/Huh7.5.1 full lifecycle model of HCV was used to study the antiviral effects of naringenin on viral replication, assembly, and production. Activation of
PPAR? was elucidated using GAL4-PPAR? fusion reporters, PPRE reporters, qRT-PCR, and metabolic studies. Metabolic results were confirmed in primary human hepatocytes
Submitted by admin on Tue, 05/03/2011 - 21:06
Hepatitis
Autoimmune Hepatitis, Toxic Hepatitis, Hepatitis B, Hepatitis C
Wobenzym in complex
therapy of chronic liver diseases
Vasilenko A. M., Svec S. V. Wobenzym in complex
therapy of chronic liver diseases. State Medical Academy in
Dnepropetrovsk. II National Congress of Rheumatologists in the
Ukraine, Kiev, 1997
Current complex therapy of chronic liver diseases focuses on
elimination of basic pathogenetic syndroms of the disease.
Glucocorticoids (GC) are the most effective in the treatment of
chronic autoimmune hepatitis (CAH) and active liver cirrhosis (LC)
with a significant autoimmune process. They appear to be effective
regulators of immune reaction which suppress antibody production.
One of the undesirable side-effects of GC is formation of
circulating middle size immune complexes (CIC) which intensify
cytolytic syndrom ( 1, 2, 4). One of the main characteristics of CIC
- pathogenesity - is mainly determined by the size of complexes.
Pathogenesity is caused, among others factors, also by a
quantitative relation between antigen and antibody. During
overproduction of antibodies against any antigen or in the case of
equivalent relation when antigen is fully or partially bound, large
CIC are formed. Mild excess of antigen over appropriate antibody
(ratio 3:2) leads to a formation of middle sized immune complexes.
Insufficient antibody production causes a formation of low molecular
weight complexes. Literature data (l, 2, 4) show that cytolysis is
higher when middle size CIC prevail. Optimal conditions for middle
size CIC formation arise in 2nd - 3rd week of the treatment by big
doses of GC. Wide use of GC is limited also by risk of possible
side-effects: pathological changes in organs of digestive system and
kidney, insufficient anti-inflammatory effect, impossible induction
of remission of the disease. All above mentioned facts speak for a
necessity to search for new methods to treat chronic liver diseases.
Systemic enzyme therapy seems to be one of the prospective options.
Submitted by admin on Fri, 04/22/2011 - 13:35
Hepatitis C is an infectious disease of the liver that can cause miserable symptoms including fatigue, lack of appetite, abdominal pain, nausea and vomiting. Caused by a virus, hepatitis C affects about 200 million people worldwide. In the U.S. alone, one to two percent of the population is infected. Not only can this infectious disease cause scarring of the liver, cirrhosis, and eventually liver failure, but a significant number of people with hepatitis C also develop sometimes fatal liver disease or cancer.
Submitted by admin on Sun, 02/13/2011 - 19:42
Executive Summary
The Hepatitis C Trust held a web-based survey from April 2006 to September 2007 that asked about people’s experience of anti-viral hepatitis C treatment and in particular how they felt up to 3 years after finishing the treatment. 500 respondents completed the questionnaire. Key findings: - * 90% of people reported ongoing symptoms/side effects for longer than 12 months after treatment ended.
- * The five most frequently reported post treatment symptoms/side effects were fatigue, joint aches/pains, brain fog, depression and mood swings.
- * Regardless of SVR (sustained virological response), 40% of people felt worse after treatment than before and 31% felt better.
- For those who had attained SVR
37% felt better and 36% felt worse
Submitted by admin on Tue, 11/30/2010 - 19:42
A new study by the Washington Post finds that women who take a popular hormone replacement drug after menopause not only increase their chances of getting breast cancer but also seem to face an increased risk of dying from the disease. The Washington Post article based its report on a landmark federal study.
 |
|
|
|
|
